Daiichi Sankyo

The US Food and Drug Administration (FDA) has approved Daiichi Sankyo’s quizartinib (Vanflyta) for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3 internal tandem duplication (ITD)-positive. It is approved with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy. The FDA also […]

The Prescription Medicines Code of Practice Authority (PMCPA), a self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, have opened cases against Leo Pharma, AstraZeneca and Daiichi Sankyo for bringing discredit upon, and reducing confidence in, the pharmaceutical industry. AstraZeneca   AstraZeneca was ruled in breach […]

Lu Rahman looks at how opportunities are growing in Japanese drug development and where innovation is coming from. Japan is a fascinating drug discovery and development market. A strong pharmaceutical sector (some reports place it second globally behind the US), an ageing population and a tranche of expertise, put the country in a good position. […]